ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026.
GSK plc today announced that Harmony Row Acquisition Co. has commenced a tender offer to purchase all of the shares of Nuvalent, Inc.
More than 3 million cases of cUTIs are treated annually in the US with up to a third of patients impacted by resistant infections.
VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments.
Acquisition expected to be accretive to sales & core operating profit in 2027 & core EPS in 2029 inclusive of synergies and reprioritisation
Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity.
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
Patient preference and adherence research highlight potential of long-acting dosing regimens to improve clinical outcomes in severe asthma
Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments
Designations recognise potential for efimosfermin to address significant unmet medical need & reflect momentum in GSKs liver health pipeline
Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. against TESARO’s claim for anticipatory breach.
As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep provides a new and needed mechanism of action in therapy.
GSK today announced the completion of its previously announced acquisition of 35Pharma Inc.